
## Staffan Hägg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4855392/publications.pdf Version: 2024-02-01



**STAFEAN ΗÃØC** 

#	Article	IF	CITATIONS
1	Current Evidence on Abuse and Misuse of Gabapentinoids. Drug Safety, 2020, 43, 1235-1254.	1.4	48
2	Clinical relevance of alerts from a decision support system, PHARAO, for drug safety assessment in the older adults. BMC Geriatrics, 2019, 19, 164.	1.1	8
3	Use of non-benzodiazepine hypnotics is associated with falls in nursing home residents: a longitudinal cohort study. Aging Clinical and Experimental Research, 2019, 31, 1087-1095.	1.4	10
4	The Cone Evasion Walk test: Reliability and validity in acute stroke. Physiotherapy Research International, 2019, 24, e1744.	0.7	2
5	Venous Thromboembolism During Treatment with Antipsychotics: A Review of Current Evidence. CNS Drugs, 2018, 32, 47-64.	2.7	48
6	Comparing Methods for Estimating Direct Costs of Adverse Drug Events. Value in Health, 2017, 20, 1299-1310.	0.1	6
7	Direct and indirect costs for adverse drug events identified in medical records across care levels, and their distribution among payers. Research in Social and Administrative Pharmacy, 2017, 13, 1151-1158.	1.5	4
8	Non-prescribed use of psychoactive prescription drugs among drug-impaired drivers in Sweden. Drug and Alcohol Dependence, 2016, 161, 77-85.	1.6	16
9	On the pedagogy of pharmacological communication: a study of final semester health science students. BMC Medical Education, 2015, 15, 186.	1.0	3
10	The understanding of core pharmacological concepts among health care students in their final semester. BMC Medical Education, 2015, 15, 235.	1.0	12
11	The impact of a changed legislation on reporting of adverse drug reactions in Sweden, with focus on nurses' reporting. European Journal of Clinical Pharmacology, 2015, 71, 631-636.	0.8	14
12	Zinc Induces a Bell-shaped Proliferative Dose-response Effect in Cultured Smooth Muscle Cells From Benign Prostatic Hyperplasia. Urology, 2015, 85, 704.e15-704.e19.	0.5	4
13	Potentially inappropriate prescribing and adverse drug reactions in the elderly: a population-based study. European Journal of Clinical Pharmacology, 2015, 71, 1525-1533.	0.8	104
14	Adherence to Antihypertensive Therapy and Elevated Blood Pressure: Should We Consider the Use of Multiple Medications?. PLoS ONE, 2015, 10, e0137451.	1.1	45
15	Economic Impact of Adverse Drug Events – A Retrospective Population-Based Cohort Study of 4970 Adults. PLoS ONE, 2014, 9, e92061.	1.1	50
16	Prevalence, nature and potential preventability of adverse drug events – a populationâ€based medical record study of 4970 adults. British Journal of Clinical Pharmacology, 2014, 78, 170-183.	1.1	58
17	Medication errors related to transdermal opioid patches: lessons from a regional incident reporting system. BMC Pharmacology & Toxicology, 2014, 15, 31.	1.0	9
18	Timeâ€ŧoâ€onset in spontaneous reports: the possibility to detect the unexpected. Pharmacoepidemiology and Drug Safety, 2013, 22, 556-557.	0.9	5

Staffan HÃ**ö**g

#	Article	IF	CITATIONS
19	Key Elements in Adverse Drug Interaction Safety Signals. Drug Safety, 2013, 36, 63-70.	1.4	7
20	ABCB1 gene polymorphisms are associated with suicide in forensic autopsies. Pharmacogenetics and Genomics, 2013, 23, 463-469.	0.7	13
21	Refill adherence and selfâ€reported adverse drug reactions and subâ€therapeutic effects: a populationâ€based study. Pharmacoepidemiology and Drug Safety, 2013, 22, 1317-1325.	0.9	6
22	Prevalence and Perceived Preventability of Self-Reported Adverse Drug Events – A Population-Based Survey of 7099 Adults. PLoS ONE, 2013, 8, e73166.	1.1	37
23	The Impact of Duration of Treatment on Reported Time-to-Onset in Spontaneous Reporting Systems for Pharmacovigilance. PLoS ONE, 2013, 8, e68938.	1.1	7
24	A Fatal Outcome After Unintentional Overdosing of Rivastigmine Patches. Current Drug Safety, 2012, 7, 30-32.	0.3	21
25	In vitro effects of serotonin and noradrenaline reuptake inhibitors on human platelet adhesion and coagulation. Pharmacological Reports, 2012, 64, 979-983.	1.5	39
26	Methods for Assessing the Preventability of Adverse Drug Events. Drug Safety, 2012, 35, 105-126.	1.4	43
27	Venous Thromboembolism in Recipients of Antipsychotics. CNS Drugs, 2012, 26, 649-662.	2.7	47
28	Modelling drug-related morbidity in Sweden using an expert panel of physicians. European Journal of Clinical Pharmacology, 2012, 68, 1309-1319.	0.8	6
29	Modelling drug-related morbidity in Sweden using an expert panel of pharmacists'. International Journal of Clinical Pharmacy, 2012, 34, 538-546.	1.0	10
30	A prospective analysis of the preventability of adverse drug reactions reported in Sweden. European Journal of Clinical Pharmacology, 2012, 68, 1183-1189.	0.8	15
31	Percentage of Patients with Preventable Adverse Drug Reactions and Preventability of Adverse Drug Reactions–ÂA Meta-Analysis. PLoS ONE, 2012, 7, e33236.	1.1	224
32	Effects of Cocoa Extract and Dark Chocolate on Angiotensin-converting Enzyme and Nitric Oxide in Human Endothelial Cells and Healthy Volunteers–A Nutrigenomics Perspective. Journal of Cardiovascular Pharmacology, 2011, 57, 44-50.	0.8	55
33	Impact of information letters on the reporting rate of adverse drug reactions and the quality of the reports: a randomized controlled study. BMC Clinical Pharmacology, 2011, 11, 14.	2.5	22
34	Preventable drug related mortality in a Swedish population. Pharmacoepidemiology and Drug Safety, 2010, 19, 211-215.	0.9	20
35	Antihypertensive drugs and erectile dysfunction as seen in spontaneous reports, with focus on angiotensin II type 1 receptor blockers. Drug, Healthcare and Patient Safety, 2010, 2, 21.	1.0	9
36	Effects of green tea, black tea and Rooibos tea on angiotensin-converting enzyme and nitric oxide in healthy volunteers. Public Health Nutrition, 2010, 13, 730.	1.1	42

Staffan HÃ**ö**g

#	Article	IF	CITATIONS
37	Antipsychotics and risk of venous thromboembolism: A population-based case-control study. Clinical Epidemiology, 2009, 1, 19.	1.5	34
38	Spontaneously reported adverse reactions in association with complementary and alternative medicine substances in Sweden. Pharmacoepidemiology and Drug Safety, 2009, 18, 1039-1047.	0.9	60
39	Tramadol dependence: a survey of spontaneously reported cases in Sweden. Pharmacoepidemiology and Drug Safety, 2009, 18, 1192-1198.	0.9	63
40	Fatal drug poisonings in a Swedish general population. BMC Clinical Pharmacology, 2009, 9, 7.	2.5	22
41	Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction. British Journal of Clinical Pharmacology, 2009, 68, 427-434.	1.1	48
42	Risk of venous thromboembolism due to antipsychotic drug therapy. Expert Opinion on Drug Safety, 2009, 8, 537-547.	1.0	76
43	Sudden Cardiac Death in Users of Second-Generation Antipsychotics. Journal of Clinical Psychiatry, 2009, 70, 1725-1726.	1.1	3
44	Drugâ€induced torsades de pointes: a review of the Swedish pharmacovigilance database. Pharmacoepidemiology and Drug Safety, 2008, 17, 587-592.	0.9	70
45	Incidence of fatal adverse drug reactions: a population based study. British Journal of Clinical Pharmacology, 2008, 65, 573-579.	1.1	265
46	Associations Between Venous Thromboembolism andÂAntipsychotics. Drug Safety, 2008, 31, 685-694.	1.4	66
47	Urinary Detection Times and Metabolite/Parent Compound Ratios After a Single Dose of Buprenorphine. Journal of Analytical Toxicology, 2008, 32, 586-593.	1.7	35
48	Antipsychotics associated with pulmonary embolism in a Swedish medicolegal autopsy series. International Clinical Psychopharmacology, 2008, 23, 263-268.	0.9	31
49	Therapeutic Drug Monitoring of Ziprasidone in a Clinical Treatment Setting. Therapeutic Drug Monitoring, 2008, 30, 682-688.	1.0	15
50	Serum Levels of Olanzapine in a Non-Fatal Overdose. Journal of Analytical Toxicology, 2007, 31, 119-121.	1.7	14
51	Fatal unintentional intoxications with tramadol during 1995–2005. Forensic Science International, 2007, 173, 107-111.	1.3	81
52	Spontaneously reported fatal suspected adverse drug reactions: a 10-year survey from Sweden. Pharmacoepidemiology and Drug Safety, 2007, 16, 173-180.	0.9	29
53	Cerebral haemorrhage induced by warfarin—the influence of drug–drug interactions. Pharmacoepidemiology and Drug Safety, 2007, 16, 309-315.	0.9	30
54	IN VITRO EFFECTS OF ANTIPSYCHOTICS ON HUMAN PLATELET ADHESION AND AGGREGATION AND PLASMA COAGULATION. Clinical and Experimental Pharmacology and Physiology, 2007, 34, 775-780.	0.9	75

Staffan HÃ**ö**g

#	Article	IF	CITATIONS
55	High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. International Clinical Psychopharmacology, 2006, 21, 93-98.	0.9	116
56	Incidence of venous thromboembolism in young Swedish women and possibly preventable cases among combined oral contraceptive users. Acta Obstetricia Et Gynecologica Scandinavica, 2004, 83, 674-681.	1.3	44
57	Clozapine and pulmonary embolism. Acta Psychiatrica Scandinavica, 2003, 108, 76-77.	2.2	20
58	Hepatic injury and pancreatitis during treatment with serotonin reuptake inhibitors. International Clinical Psychopharmacology, 2003, 18, 157-161.	0.9	11
59	Long-term combination treatment with clozapine and filgrastim in patients with clozapine-induced agranulocytosis. International Clinical Psychopharmacology, 2003, 18, 173-174.	0.9	41
60	Olanzapine and venous thromboembolism. International Clinical Psychopharmacology, 2003, 18, 299-300.	0.9	23
61	Glucose Intolerance with Atypical Antipsychotics. Drug Safety, 2002, 25, 1107-1116.	1.4	104
62	Antipsychotic-Induced Venous Thromboembolism. CNS Drugs, 2002, 16, 765-776.	2.7	106
63	Adverse drug reactions as a cause for admissions to a department of internal medicine. Pharmacoepidemiology and Drug Safety, 2002, 11, 65-72.	0.9	168
64	Utilization pattern of metamizole in northern Sweden and risk estimates of agranulocytosis. Pharmacoepidemiology and Drug Safety, 2002, 11, 239-245.	0.9	41
65	Therapeutic approaches to bulimia nervosa. Expert Opinion on Therapeutic Patents, 2001, 11, 463-477.	2.4	2
66	Repeated Episodes of Hypothermia in a Subject Treated With Haloperidol, Levomepromazine, Olanzapine, and Thioridazine. Journal of Clinical Psychopharmacology, 2001, 21, 113-115.	0.7	30
67	Myocarditis Related to Clozapine Treatment. Journal of Clinical Psychopharmacology, 2001, 21, 382-388.	0.7	120
68	The major fluvoxamine metabolite in urine is formed by CYP2D6. European Journal of Clinical Pharmacology, 2001, 57, 653-658.	0.8	51
69	Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. British Journal of Clinical Pharmacology, 2001, 51, 169-173.	1.1	128
70	Leptin Concentrations Are Increased in Subjects Treated With Clozapine or Conventional Antipsychotics. Journal of Clinical Psychiatry, 2001, 62, 843-848.	1.1	66
71	Effect of caffeine on clozapine pharmacokinetics in healthy volunteers. British Journal of Clinical Pharmacology, 2000, 49, 59-63.	1.1	60
72	Excretion of fluvoxamine into breast milk. British Journal of Clinical Pharmacology, 2000, 49, 286-288.	1.1	36

Staffan HÃ**g**g

#	Article	IF	CITATIONS
73	Citalopram pharmacokinetics in patients with chronic renal failure and the effect of haemodialysis. European Journal of Clinical Pharmacology, 2000, 56, 699-703.	0.8	32
74	Association of venous thromboembolism and clozapine. Lancet, The, 2000, 355, 1155-1156.	6.3	152
75	Analgesics and Breast-Feeding. Paediatric Drugs, 2000, 2, 223-238.	1.3	79
76	Anticonvulsant Use During Lactation. Drug Safety, 2000, 22, 425-440.	1.4	66
77	Lack of correlation between fluvoxamine clearance and CYP1A2 activity as measured by systemic caffeine clearance. European Journal of Clinical Pharmacology, 1999, 54, 943-946.	0.8	25
78	Absence of interaction between erythromycin and a single dose of clozapine. European Journal of Clinical Pharmacology, 1999, 55, 221-226.	0.8	46
79	Enhanced platelet serotonin 5-HT2A receptor binding in anorexia nervosa and bulimia nervosa. European Neuropsychopharmacology, 1999, 9, 469-473.	0.3	16
80	Prolonged Sedation and Slowly Decreasing Clozapine Serum Concentrations After an Overdose. Journal of Clinical Psychopharmacology, 1999, 19, 282-284.	0.7	17
81	Excretion of Paroxetine Into Breast Milk. Journal of Clinical Psychiatry, 1999, 60, 519-523.	1.1	73
82	Nonâ€linear fluvoxamine disposition. British Journal of Clinical Pharmacology, 1998, 45, 257-263.	1.1	97
83	Excretion of Psychotropic Drugs into Breast Milk. CNS Drugs, 1998, 9, 111-134.	2.7	37
84	Prevalence of Diabetes and Impaired Glucose Tolerance in Patients Treated With Clozapine Compared With Patients Treated With Conventional Depot Neuroleptic Medications. Journal of Clinical Psychiatry, 1998, 59, 294-299.	1.1	189
85	Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms. European Journal of Clinical Pharmacology, 1997, 52, 129-133.	0.8	70